TRAWS PHARMA(TRAW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TRAW TRAWS PHARMA

Not Yet Opened 06-02 16:00:00 EDT

1.42

-0.05

-3.40%

盘后1.42

+0.000.00%

19:56 EDT

High1.46	Low1.40	Vol292.32K
Open1.46	D1 Closing1.47	Amplitude4.08%
Mkt Cap21.51M	Tradable Cap14.71M	Total Shares15.15M
T/O418.41K	T/O Rate2.82%	Tradable Shares10.36M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TRAW","market":"US","secType":"STK","nameCN":"TRAWS PHARMA","latestPrice":1.42,"timestamp":1780430400000,"preClose":1.47,"halted":0,"volume":292317,"hourTrading":{"tag":"盘后","latestPrice":1.42,"preClose":1.42,"latestTime":"19:56 EDT","volume":33087,"amount":46633.3059,"timestamp":1780444587249,"change":0,"changeRate":0,"amplitude":0.028169},"delay":0,"changeRate":-0.0340136054421769,"floatShares":10358000,"shares":15150700,"eps":-1.520743,"marketStatus":"Not Yet Opened","change":-0.05,"latestTime":"06-02 16:00:00 EDT","open":1.46,"high":1.46,"low":1.4,"amount":418406.27174309996,"amplitude":0.040816,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.520743,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780473600000},"marketStatusCode":0,"adr":0,"listingDate":1374724800000,"exchange":"NASDAQ","adjPreClose":1.47,"preHourTrading":{"tag":"盘前","latestPrice":1.4453,"preClose":1.47,"latestTime":"08:31 EDT","volume":2499,"amount":3517.2098031,"timestamp":1780403496567,"change":-0.0247,"changeRate":-0.016803,"amplitude":0.061224},"postHourTrading":{"tag":"盘后","latestPrice":1.42,"preClose":1.42,"latestTime":"19:56 EDT","volume":33087,"amount":46633.3059,"timestamp":1780444587249,"change":0,"changeRate":0,"amplitude":0.028169},"volumeRatio":0.47963,"impliedVol":1.6331,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/TRAW/tweets","defaultTab":"tweets","newsList":[{"id":"2638107688","title":"Traws Pharma advances dual-strike broad-spectrum antiviral program targeting Hantavirus and Ebola outbreaks","url":"https://stock-news.laohu8.com/highlight/detail?id=2638107688","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638107688?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:51","pubTimestamp":1779886289,"startTime":"0","endTime":"0","summary":"Traws Pharma advanced a proprietary broad-spectrum antiviral combination targeting ongoing Hantavirus and Ebola outbreaks, with potential utility against Lassa.Program centers on a dual mechanism to deplete host nucleotides, then drive viral RdRp to incorporate nucleoside mimics to halt replication.Both components have prior human safety data as single agents, supporting a lower-dose combination strategy to reduce toxicity risk.Non-clinical studies are underway in validated Hantavirus and Ebola animal models, using BSL-3 and BSL-4 laboratories.Chemical development and manufacturing scale-up is running in parallel to support potential emergency supply, stockpiling, and expedited regulatory engagement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or le","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL4l1kxQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638886056","title":"Traws Pharma Inc - to Develop Local Manufacturing in Nigeria With Nafdac","url":"https://stock-news.laohu8.com/highlight/detail?id=2638886056","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638886056?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:45","pubTimestamp":1779885900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUA6PQ7QW:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638688604","title":"Traws Pharma Inc - Plans Interactions With Cdc, Nafdac, AMA to Fast-Track Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2638688604","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638688604?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:45","pubTimestamp":1779885900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUA6PQ7QW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638168860","title":"Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks","url":"https://stock-news.laohu8.com/highlight/detail?id=2638168860","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638168860?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:45","pubTimestamp":1779885900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUA6PQ7QW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638523546","title":"Traws Pharma sets up at-the-market equity offering of up to $3.13 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2638523546","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638523546?lang=en_us&edition=fundamental","pubTime":"2026-05-27 05:10","pubTimestamp":1779829847,"startTime":"0","endTime":"0","summary":"Traws Pharma entered an at-the-market equity distribution agreement with Citizens JMP Securities for up to USD 50 million of common stock.Current Form S-3 “baby shelf” limit caps near-term sales under the prospectus supplements to USD 3.13 million.Shares may be sold from time to time through Citizens, acting as sales agent or principal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL5YXMv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637141003","title":"BRIEF-Traws Pharma Inc Files For Offering Of Up To $3.1 Million In Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2637141003","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637141003?lang=en_us&edition=fundamental","pubTime":"2026-05-22 20:55","pubTimestamp":1779454554,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Inc Files For Offering Of Up To $3.1 Million In Common Stock May 22  - Traws Pharma Inc TRAW.O:TRAWS PHARMA INC - FILES FOR OFFERING OF UP TO $3.1 MILLION IN COMMON STOCK - SEC FILINGSource text: [ID:n0001104659-26-065444]Further company coverage: TRAW.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nFWN41Z055:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637319050","title":"Traws Pharma Inc - Files for Offering of up to $3.1 Mln in Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2637319050","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637319050?lang=en_us&edition=fundamental","pubTime":"2026-05-22 20:01","pubTimestamp":1779451314,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nFWN41Z055:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637290688","title":"FACTBOX-Hantavirus vaccines and treatments under development","url":"https://stock-news.laohu8.com/highlight/detail?id=2637290688","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637290688?lang=en_us&edition=fundamental","pubTime":"2026-05-21 00:13","pubTimestamp":1779293603,"startTime":"0","endTime":"0","summary":"May 20  - Drug development efforts targeting the rare hantavirus infection have gained renewed attention following a deadly outbreak aboard the Dutch cruise ship MV Hondius last month.There are currently no approved vaccines or targeted antiviral treatments, and care is largely supportive. Here are some companies and institutions which have hantavirus treatments or vaccines under development:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nL4N41O18Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4007","TRAW","BK4551","BK4139","BK4534","BK4568","MRNA","MRNX","MRNY","BK4501","BK4548","BK4533","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636484670","title":"Traws Pharma Price Target Maintained With a $8.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2636484670","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636484670?lang=en_us&edition=fundamental","pubTime":"2026-05-20 18:56","pubTimestamp":1779274560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TRAW/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 20, 2026 06:56 ET (10:56 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635086183","title":"Traws Pharma Q1 EPS $(0.53) Beats $(0.56) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635086183","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635086183?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:09","pubTimestamp":1778843342,"startTime":"0","endTime":"0","summary":"Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 66.46 percent increase over losses of $(1.58) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52591890/traws-pharma-q1-eps-0-53-beats-0-56-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635863630","title":"Traws Pharma Q1 FY26 net loss widens to $7.1 million; R&D expense rises to $4.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635863630","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635863630?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:01","pubTimestamp":1778842872,"startTime":"0","endTime":"0","summary":"Traws Pharma posted a net loss of $7.1 million, or $0.53 per share, for the quarter ended March 31, 2026, swinging from net income of $21.5 million a year earlier.Revenue was no revenue, versus $57,000 in the prior-year quarter.R&D expense rose to $4.9 million from $2.5 million, while G&A expense fell to $2 million from $2.8 million.Cash and cash equivalents totaled $3.1 million at March 31, down from $3.8 million at year-end 2025.Management said an up to $60 million PIPE financing, including $10 million upfront, is expected to fund operations into Q1 2027 as tivoxavir marboxil advances toward a single-dose influenza challenge trial slated to start in Q2 2026, while the company works to lift an FDA clinical hold and moves to advance a hantavirus treatment candidate.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL6vK1qs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","TRAW","SG9999014039.USD","BK4588","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","LU0314104364.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","IE00BN0W2W23.USD","BK4585","IE00B3QW5Z07.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4007","SG9999014021.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635086356","title":"Traws Pharma Inc: Traws Plans to Move Rapidly to Advance Clinical Candidate for Hantavirus Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2635086356","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635086356?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:00","pubTimestamp":1778842800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLX50EC77:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635085011","title":"Traws Pharma Inc Q1 Revenue USD 0","url":"https://stock-news.laohu8.com/highlight/detail?id=2635085011","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635085011?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:00","pubTimestamp":1778842800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLX50EC77:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635086549","title":"Press Release: Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635086549","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635086549?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:00","pubTimestamp":1778842800,"startTime":"0","endTime":"0","summary":"Private financing of up to $60M offering of common stock  and milestone-based warrants expected to support operations into Q1 2027. Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent. Advancing clinical candidates for the treatment of hantavirus infections. \"Q1 2026 was a period of meaningful progress for Traws. The recently announced private financing of up to $60 million in gross proceeds provides us with a clear runway into Q1 2027 and supports our ability to execute on our key programs. We are advancing TXM toward a human challenge trial as a once-monthly prophylactic agent against seasonal influenza, which is scheduled to be initiated in Q2 2026. Separately, we will be actively engaging with the FDA to resolve the clinical hold and enable initiation of global studies by year end,\" commented Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma. \"Our pipeline now also includes a potential antiviral therapy for hantav","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","PIPE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634236725","title":"Here's how much Moderna's stock has rallied off renewed focus on hantavirus research","url":"https://stock-news.laohu8.com/highlight/detail?id=2634236725","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634236725?lang=en_us&edition=fundamental","pubTime":"2026-05-12 01:17","pubTimestamp":1778519820,"startTime":"0","endTime":"0","summary":"There are now at least 11 suspected cases of a rare type of hantavirus responsible for an outbreak on a cruise ship. An American citizen on Sunday takes photos on his phone after he was evacuated from the MV Hondius in Tenerife, which is part of Spain's Canary Islands. . As the public grows increasingly concerned about the possibility that a hantavirus outbreak on a cruise could spark a new pandemic, Moderna, the biotech company whose quick work developing a COVID-19 vaccine made it a household name, is receiving renewed attention.The company has been quietly researching hantaviruses for years, and that work is gaining new relevance. Moderna has been studying hantaviruses with the U.S. Army and began a partnership in 2024 with the Vaccine Innovation Center at the Korea University College of Medicine to develop mRNA hantavirus vaccines.Moderna's stock  rallied amid the renewed interest in the partnerships; its shares were up about 5% in early trading on Monday morning before falling 2%.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"c3eded8fb3ee9cd51304c05def1e555f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU0058720904.USD","BK4548","LU0109394709.USD","BK4551","LU0823416689.USD","LU2324357040.USD","MRNY","BK4566","LU1934455863.HKD","LU0289739699.SGD","LU0122379950.USD","IE00BKVL7J92.USD","LU1066053197.SGD","IE00B7SZLL34.SGD","BK4568","IE00BSNM7G36.USD","SG9999015986.USD","IE00B3T34201.USD","SG9999015952.SGD","LU1585245621.USD","SG9999015978.USD","IE0002270589.USD","GILD","LU0234570918.USD","BK4007","LU1023059063.AUD","LU0965508806.USD","LU1066051498.USD","LU1839511570.USD","LU1934455194.USD","LU2468319806.SGD","LU0320765992.SGD","LU1057294990.SGD","LU1430594728.SGD","LU0889565916.HKD","BK4585","BK4532","LU0965509101.SGD","LU2112291526.USD","IE00B19Z3B42.SGD","LU1061106388.HKD","MRNA","TRAW","IE00B19Z3581.USD","LU0861579265.USD","LU2087621335.USD","MRNX","BK4139","LU0965509283.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634755284","title":"Traws Pharma Inc  expected to post a loss of 74 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634755284","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634755284?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:16","pubTimestamp":1778505366,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc  expected to post a loss of74cents a share - Earnings Preview Traws Pharma Inc TRAW.OQ TRAW.O is expected to  report resultson May 13 (estimated) for the period ending March 31 2026LS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O1EO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634498121","title":"Traws Pharma files to sell 35.9M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2634498121","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634498121?lang=en_us&edition=fundamental","pubTime":"2026-05-09 06:46","pubTimestamp":1778280380,"startTime":"0","endTime":"0","summary":"17:05 EDT Traws Pharma (TRAW) files to sell 35.9M shares of common stock for holders Published first on TheFly – the ultimate source for real-time,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/traws-pharma-files-to-sell-35-9m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/traws-pharma-files-to-sell-35-9m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634466922","title":"Sector Update: Healthcare Stocks Lower in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2634466922","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634466922?lang=en_us&edition=fundamental","pubTime":"2026-05-09 01:50","pubTimestamp":1778262622,"startTime":"0","endTime":"0","summary":"Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index falling 1% and the State Street Healthcare Select Sector SPDR ETF  shedding 0.9%.The iShares Biotechnology ETF  was 0.4% higher.In corporate news, Zoetis  shares fell past 6% after Ameriprise downgraded the stock to hold from buy following its Q1 results Thursday. UBS cut the company's price target to $99 from $130, and Jefferies to $117 from $155.Traws Pharma  shares surged 24%. The company said Friday it plans to develop potential therapies for the treatment and prevention of hantavirus infections using its portfolio of antiviral drug candidates targeting negative-strand RNA viruses.Novo Nordisk  saw a 40% month-on-month surge in April sales of its diabetes and weight-loss drugs in India after slashing prices, despite a flood of generic versions, Bloomberg reported, citing data from market researcher Pharmarack. Novo added 0.2%.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NVOH","LU0029874061.USD","GB00BDT5M118.USD","LU2360106947.USD","LU0471298777.SGD","NVO","LU0158827781.USD","IE00B19Z9505.USD","BK4588","LU2111349929.HKD","ZTS","LU0289739699.SGD","BK4532","LABU","LU2089284900.SGD","BK4581","LU1941712348.USD","XLV","LU0058720904.USD","LU2028103732.USD","XBI","LU2308191902.HKD","LU1059921491.USD","LU0128526141.USD","BK7104","BK4585","LU2271345857.HKD","LU0345774631.USD","IBB","LU0158827948.USD","NVOX","BK4534","LU2089283258.USD","LU1236620750.USD","IE00BZ1G4Q59.USD","TRAW","LU1093756325.SGD","LU0079474960.USD","LU0471298694.HKD","LU0154236417.USD","LU1721429402.USD","LU0385154629.USD","BK4137","LU2023251221.USD","LU1941712264.USD","BK4599","LU0345774391.USD","LU1236620834.HKD","LU0107464264.USD","IE00BKVL7J92.USD","LU1721429741.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634663466","title":"There are no hantavirus treatments. The deadly cruise-ship outbreak is a 'wake-up call' to develop some.","url":"https://stock-news.laohu8.com/highlight/detail?id=2634663466","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634663466?lang=en_us&edition=fundamental","pubTime":"2026-05-09 01:43","pubTimestamp":1778262180,"startTime":"0","endTime":"0","summary":"\"Maybe this is a wake-up call,\" said Kartik Chandran, a hantavirus researcher and a professor of microbiology and immunology at the Albert Einstein College of Medicine in New York.Back in 2019, a group of scientists took $22 million from the U.S. government and developed a monoclonal antibody that appears to work in the lab against the Andes virus - which is responsible for the cruise-ship outbreak that has killed three people so far - and two other hantaviruses.But the project has since stalled. Without additional funding from the government or a nonprofit, the researchers don't have the money to put the experimental treatment through its first human studies, according to Kartik Chandran, the project's leader and a professor of microbiology and immunology at the Albert Einstein College of Medicine in New York. That's a necessary next step to bring any treatment to market.For the scientists who study hantaviruses, particularly the Andes virus, the outbreak doesn't come as a surprise. S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633127456","title":"Traws Pharma Expands Antiviral Program to Target Hantavirus Infections; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2633127456","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633127456?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:26","pubTimestamp":1778243203,"startTime":"0","endTime":"0","summary":"Traws Pharma  plans to develop potential therapies for the treatment and prevention of hantavirus infections using its existing portfolio of antiviral drug candidates targeting negative-strand RNA viruses, the company said Friday.The company said the candidates have demonstrated activity against negative-strand virus replication and could be developed as standalone or combination therapies.Traws also plans to leverage its existing development infrastructure and proprietary chemical libraries to identify optimal Hantaan virus treatments.There are currently no approved treatments for Hantaan pulmonary disease, a rodent-borne infection with human fatality rates ranging from 30% to 50%, the company said.Traws Pharma shares were up 33% in recent premarket activity on Friday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.trawspharma.com","stockEarnings":[{"period":"1week","weight":-0.1013},{"period":"1month","weight":-0.047},{"period":"3month","weight":-0.1548},{"period":"6month","weight":-0.3983},{"period":"1year","weight":0},{"period":"ytd","weight":0.2566}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.054},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.1098},{"period":"1year","weight":0.2815},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.179894},{"month":2,"riseRate":0.384615,"avgChangeRate":-0.08728},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.040526},{"month":4,"riseRate":0.230769,"avgChangeRate":-0.139367},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.053691},{"month":6,"riseRate":0.692308,"avgChangeRate":0.060154},{"month":7,"riseRate":0.25,"avgChangeRate":-0.019463},{"month":8,"riseRate":0.230769,"avgChangeRate":-0.120142},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.103896},{"month":10,"riseRate":0.230769,"avgChangeRate":-0.080722},{"month":11,"riseRate":0.461538,"avgChangeRate":-0.058331},{"month":12,"riseRate":0.307692,"avgChangeRate":0.009577}],"exchange":"NASDAQ","name":"TRAWS PHARMA","nameEN":"TRAWS PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TRAWS PHARMA(TRAW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest TRAWS PHARMA(TRAW) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"TRAWS PHARMA,TRAW,TRAWS PHARMA股票,TRAWS PHARMA股票老虎,TRAWS PHARMA股票老虎国际,TRAWS PHARMA行情,TRAWS PHARMA股票行情,TRAWS PHARMA股价,TRAWS PHARMA股市,TRAWS PHARMA股票价格,TRAWS PHARMA股票交易,TRAWS PHARMA股票购买,TRAWS PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TRAWS PHARMA(TRAW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest TRAWS PHARMA(TRAW) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}